Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

P W Kantoff1

  • 1Harvard Medical School, Boston, Massachusetts.

Current Problems in Cancer
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Bladder cancer is often preventable, with early diagnosis crucial for effective treatment. Management strategies are evolving, especially for invasive cancers, with chemotherapy showing promise for metastatic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.

Prostate cancer and prostatic diseases·2017
Same author

Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.

Prostate cancer and prostatic diseases·2016
Same author

Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.

Prostate cancer and prostatic diseases·2016
Same author

Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution.

Clinical radiology·2016
Same author

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Role of diet in prostate cancer: the epigenetic link.

Oncogene·2014
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
Same journal

Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Current problems in cancer·2026
See all related articles

Area of Science:

  • Urology
  • Oncology
  • Epidemiology

Background:

  • Bladder cancer is largely preventable, with smoking and occupational exposures as primary causes.
  • Early diagnosis is essential for optimal treatment outcomes.
  • Current management strategies for bladder cancer are evolving, particularly for invasive stages.

Purpose of the Study:

  • To review the current understanding and management of bladder cancer.
  • To discuss the evolving treatment landscape for superficial and invasive bladder cancer.
  • To highlight areas of ongoing research and clinical evaluation.

Main Methods:

  • Review of epidemiologic studies on bladder cancer causes.
  • Analysis of current diagnostic and therapeutic approaches for various bladder cancer stages.

Related Experiment Videos

  • Evaluation of treatment outcomes for superficial, invasive, and metastatic bladder cancer.

    • Main Results:

    • The majority of bladder cancers are superficial and treatable cystoscopically.
    • Intravesical therapy's role in preventing progression in high-risk superficial cases requires further study.
    • Chemotherapy demonstrates activity in metastatic bladder cancer, prolonging survival and offering remissions.

    Conclusions:

    • Bladder cancer management is dynamic, with ongoing research into bladder preservation and optimal treatment for invasive disease.
    • While cystectomy is standard for invasive cancer, selective bladder preservation is being evaluated.
    • Chemotherapy offers a promising avenue for managing metastatic bladder cancer, with potential for durable remissions.